Multidimensional Mechanistic Elucidation of Panax Notoginseng Saponins for Alcohol-Induced Osteonecrosis of the Femoral Head: Integrating Network Pharmacology, Molecular Dynamics Simulation and In Vivo Validation

Technical Summary: Multidimensional Mechanistic Elucidation of Panax Notoginseng Saponins for Alcohol-Induced Osteonecrosis of the Femoral Head

Problem Statement
Alcohol-induced osteonecrosis of the femoral head (AIONFH) is a prevalent orthopedic condition resulting from chronic alcohol abuse, characterized by disrupted femoral head perfusion, osteocyte necrosis, and structural collapse. Current hip-preserving therapies, such as statins and anticoagulants, offer limited efficacy, often necessitating total hip arthroplasty. While Panax Notoginseng Saponins (PNS) have demonstrated pro-angiogenic and anti-apoptotic properties in bone disorders, their precise molecular mechanisms in treating AIONFH remain poorly defined. This study addresses the need to systematically elucidate the active ingredients, core targets, and signaling pathways of PNS against AIONFH to facilitate its clinical translation.

Methodology
The study employed a multi-dimensional approach integrating computational prediction with in vivo validation:

1. Network Pharmacology & Machine Learning:

   • Target Screening: PNS active components and AIONFH-related targets were retrieved from databases (TCMSP, PubChem, GeneCards, OMIM, etc.). Intersection targets were identified, resulting in 18 common targets.
   • Core Target Identification: Three machine learning algorithms—Logistic Regression, Support Vector Machine-Recursive Feature Elimination (SVM-RFE), and Random Forest—were applied to the GEO dataset GSE74089 to screen for core therapeutic targets from the intersection set.
   • Enrichment Analysis: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed to identify biological processes and signaling pathways.

2. Molecular Simulation:

   • Molecular Docking: Interactions between five major PNS components (Notoginsenoside R1, Ginsenosides Rb1, Rg1, Re, Rd) and the six core targets were evaluated using AutoDock Vina.
   • Molecular Dynamics (MD): A 100 ns MD simulation was conducted using GROMACS 2022 on the complex with the highest binding affinity (Ginsenoside Re and HSD11B1). Stability was assessed via Root Mean Square Deviation (RMSD), Radius of Gyration (Rg), Root Mean Square Fluctuation (RMSF), Solvent Accessible Surface Area (SASA), and binding free energy calculations (MM/GBSA).

3. In Vivo Validation:

   • Model Establishment: An AIONFH rat model was induced via daily intragastric administration of 46% ethanol for 45 days.
   • Intervention: Rats were treated with low, medium, and high doses of PNS for 4 weeks.
   • Assessments: Pathological changes were evaluated using HE, TRAP, Alizarin Red, and ALP staining. Protein localization was analyzed via immunofluorescence, and gene expression (HSD11B1, Runx2, CTSK) was quantified using qPCR.

Key Results

• Target Identification: Network pharmacology identified 127 potential PNS targets and 18 overlapping targets with AIONFH. Machine learning algorithms converged on six core targets: FGF2, HSD11B1, BMP2, MMP13, TYMS, and VEGFA.
• Pathway Analysis: KEGG enrichment highlighted the Vascular Endothelial Growth Factor (VEGF) pathway as pivotal. GO analysis indicated significant involvement in osteoblast differentiation.
• Molecular Interaction: Molecular docking revealed that Ginsenoside Re (G-Re) exhibited the strongest binding affinity to HSD11B1 (binding energy: -12.4 kcal/mol).
• Simulation Stability: The 100 ns MD simulation confirmed the stability of the G-Re–HSD11B1 complex. RMSD values remained below 0.4 Å, Rg fluctuated minimally (2.64–2.76 Å), and stable hydrogen bonds (2–3) were maintained throughout the simulation. Residue energy decomposition identified ASP323 and ALA212 as critical contributors to binding.
• In Vivo Efficacy:
  • Histology: PNS treatment dose-dependently improved trabecular bone microstructure, reduced adipocyte hyperplasia, and decreased empty lacunae compared to the untreated AIONFH model.
  • Bone Metabolism: TRAP staining showed suppressed osteoclast overactivity, while ALP and Alizarin Red staining indicated restored osteoblast activity and calcium deposition.
  • Molecular Mechanism: Immunofluorescence and qPCR confirmed that AIONFH upregulates HSD11B1 and downregulates Runx2. PNS treatment dose-dependently suppressed HSD11B1 expression and restored Runx2 levels, particularly at medium and high doses.

Significance and Claims
The authors claim that this study establishes a rigorous "computational prediction → molecular validation → in vivo verification" research paradigm for traditional Chinese medicine. The primary significance lies in:

1. Mechanistic Elucidation: The study identifies HSD11B1 as a key therapeutic target for PNS in AIONFH, a finding presented as novel. The mechanism is proposed to involve the inhibition of HSD11B1 by Ginsenoside Re, which reduces local glucocorticoid overproduction, thereby alleviating vascular compression and breaking the ischemia-osteonecrosis cycle.
2. Multi-Link Therapeutic Effect: PNS is shown to exert therapeutic effects through a multi-component, multi-target, and multi-pathway manner, simultaneously improving perfusion (via VEGF/FGF2), balancing bone metabolism, and inhibiting osteocyte apoptosis.
3. Methodological Integration: The integration of machine learning with network pharmacology and molecular dynamics provides a robust framework for dissecting complex multi-component mechanisms, offering a scientific foundation for the clinical application of PNS in AIONFH treatment.

The authors acknowledge limitations, including the reliance on existing databases for target screening, the focus of MD simulations on a single complex (G-Re–HSD11B1), and the absence of long-term structural stability assessments in the animal model. Future work is proposed to include CRISPR/Cas9 validation and the development of composite clinical models.